Areteia Therapeutics
Areteia Therapeutics is a clinical-stage biotechnology company focused on developing novel inflammation and immunology therapies for respiratory diseases. Their lead drug candidate, dexpramipexole, is an oral eosinophil maturation inhibitor being developed as a potential first-in-class treatment for severe eosinophilic asthma. The company aims to improve patient control over their disease.
Buy Funded Startups lists
Funding Round: Series A
Funding Amount: $425M
Date: 13-Feb-2024
Investors: Viking Global Investors, Marshall Wace, Bain Capital Life Sciences, Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, Population Health Partners
Markets: Biotechnology, Pharmaceuticals, Healthtech
HQ: Chapel Hill, North Carolina, United States
Founded: 2022
Website: https://areteiatx.com
LinkedIn: https://www.linkedin.com/company/areteiatx
Twitter: https://twitter.com/aristeatx
Crunchbase: https://www.crunchbase.com/organization/areteia-therapeutics
Leave a Comment
Comments
No comments yet.